Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Treatment of schizophrenia currently includes antipsychotic medications and cognitive
therapies which improve some symptoms, but do not sufficiently restore cognitive functioning
or reduce psychosocial disability. We hypothesize that medications that specifically target
sensory information processing deficits, rather than psychotic symptoms per se, will
significantly enhance the benefits of a sensory-based targeted cognitive training (TCT)
intervention in patients with schizophrenia. We will complete a randomized, double-blind
clinical trial to: 1) confirm that the drug memantine augments TCT learning; 2) determine
whether memantine enhances the clinical benefits from a full 30 session course of TCT vs. TCT
plus placebo in antipsychotic- medicated schizophrenia patients, and 3) determine if
memantine's enhancement of TCT is most effective in biomarker-defined subgroups of patients.